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We identified Inquilinus limosus, a recently described α-
proteobacterium, in sputum of 2 patients with cystic fibrosis
whose respiratory tracts were persistently colonized for >9
months. We present data on the epidemiology, antimicrobial
susceptibility, and molecular characteristics of I. limosus.
C
hronic microbial colonization of the respiratory tract,
leading to exacerbations of pulmonary infection, is the
major cause of disease and death in patients with cystic
fibrosis (CF). Typical pathogens in respiratory secretions
of patients with CF include Pseudomonas aeruginosa,
Staphylococcus aureus, Haemophilus influenzae, and
Burkholderia cepacia complex (1–3). Other gram-negative
glucose nonfermenters, such as Achromobacter xylosoxi-
dans, B. gladioli, Ralstonia pickettii, and Stenotro-
phomonas maltophilia are also occasionally recovered
from respiratory samples from CF patients, but their path-
ogenic importance remains to be clarified (2–4). 
Determining the clinical relevance of nonfermentative
microbes is hampered by the difficulty in identifying these
pathogens by conventional laboratory techniques. Recent
studies that applied molecular approaches to identify
unusual pathogens in patients with CF showed various
infrequently encountered and novel species (4–7). In 1 of
these studies, the gram-negative nonfermentative species
Inquilinus limosus was newly described in respiratory
secretions of 8 patients with CF in the United States (8). I.
limosus belongs to the α-proteobacteria and is, thus, not
closely related to B. cepacia complex or P. aeruginosa (8). 
To detect unusual gram-negative microbes in respirato-
ry samples, we screened all patients attending the CF clin-
ic of the University Hospital, Ulm, Germany, from May
2002 to September 2004 (N = 85 patients). Respiratory
samples (N = 459 samples) were plated with a 10-µL loop
on sheep blood agar (Heipha, Heidelberg, Germany),
MacConkey agar (Heipha), and B. cepacia complex selec-
tive agar (containing 100 mg/Lticarcillin and 300,000 IU/L
polymyxin B, MAST Diagnostica, Reinfeld, Germany). All
plates were incubated for 48 h at 36°C under ambient air,
and the B. cepacia complex selective agar was incubated
another 5 days at room temperature.  I. limosus was recov-
ered from sputum samples of 2 patients (0.9%).
Case Reports
Patient 1
Strain A was isolated from a 17-year-old male patient
with CF with persistent colonization of the respiratory tract
since childhood with S. aureus, P. aeruginosa, including the
mucoid variant, and H. influenzae. In the initial sputum
sample, apart from ≈106 CFU/mL of  S. aureus, 105
CFU/mL of mucoid P. aeruginosa, and 103 CFU/mL of
Candida albicans, 104 CFU/mLof a mucoid gram-negative
rod was isolated from B. cepacia complex selective agar
after 6 days of incubation. The isolate had positive oxidase
and catalase reaction, but failed to grow on MacConkey
agar. It was identified by using Api 20NE as Sphingomonas
paucimobilis with questionable profile (Code 0427544).
Final identification of I. limosus was achieved by sequenc-
ing the 16S rRNAgene with the primers 16Sfor and 16Srev
(9) and a Dye Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems, Warrington, United
Kingdom) on a 310 Genetic Analyser (Abi Prism). The iso-
late showed 99.8% sequence homology to the 16S rDNA
sequence of the I. limosus type strain (LMG 20952T) by
using the BLAST algorithm.
During sequence analysis, we discovered a mistake in
the I. limosus type strain 16S rDNA sequence deposited in
GenBank (accession no. AY043374): the CGGGTC motif,
repeated twice from base 956 to 967 in AY043374, is only
found once in the type strain’s 16S rRNA gene, such as in
the Inquilinus sp. strain AU1979 (accession no. AY043375
[8]) and in our isolates. We performed susceptibility test-
ing by using Etest (VIVA Diagnostics, Solna, Sweden) on
Mueller-Hinton agar, incubated at 36°C for 48 h. In addi-
tion, susceptibility testing against colistin was performed
by disk diffusion with 10-µg disks (BD, Heidelberg,
Germany) on Mueller-Hinton agar (McFarland 0.5, 48 h
incubation). All results are shown in the Table. At the time
of sputum sampling, the patient was clinically well, with
normal values of C-reactive protein, leukocytes, and ery-
throcyte sedimentation rate. He regularly played soccer. A
lung function test was not done. Two weeks after his visit,
an elective 14-day course of antimicrobial therapy was ini-
tiated consisting of intravenous (IV) ceftazidime (3 g 3
times daily) and IV tobramycin (500 mg once daily)
because of P. aeruginosa colonization. 
Five and a half months later, the patient was seen in the
CF clinic again. He was still in very good clinical condi-
tion. Results of lung function tests conducted 6 weeks after
his first visit and at his second visit were the following:
vital capacity, 3.27l/3.34l (77%/74% of predicted vital
capacity); and forced expiratory volume, 1 s 2.81l/2.89l
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Sputum culture showed ≈106 CFU/mL of S. aureus, 104
CFU/mL of mucoid P. aeruginosa, 103 CFU/mL of
Aspergillus fumigatus, and again 103 CFU/mL of I. limo-
sus. We performed pulsed-field gel electrophoresis
(PFGE) of the isolates with the CHEF DRIII equipment
(BioRad, Munich,Germany) in 1% agarose at 14°C and a
constant voltage of 200 V (10), with the restriction enzyme
XbaI (11). Results showed that the strain (A-2) was identi-
cal to the former isolate of the same patient (A-1) (Figure).
A14-day course of oral ciprofloxacin (750 mg twice daily)
was initiated because of P. aeruginosa colonization. 
Four months later, the strain was still detected in his
sputum. The isolate (A-3) grew in low quantities (103
CFU/mL) and was accompanied by 106 CFU/mL of  S.
aureus, 106 CFU/mL of mucoid P. aeruginosa, 103
CFU/mL of A. fumigatus, and 104 CFU/mL of C. albicans.
PFGE showed identity with the former strains (Figure),
and antimicrobial susceptibility was unchanged (Table).
Lung function test showed a vital capacity of 3.81l (68%
of predicted vital capacity) and a forced expiratory volume
of 3.25l (71% of predicted forced expiratory volume), and
the patient was in good health. More than 2 months later,
the I. limosus strain was no longer cultured from his spu-
tum, while P. aeruginosa (103 CFU/mL), S. aureus (106
CFU/mL), and C. albicans (103 CFU/mL) were still found. 
Patient 2
Strain B was isolated from a sputum sample of a 14-
year-old female patient with CF with respiratory coloniza-
tion since childhood with P. aeruginosa, including the
mucoid variant, and H. influenzae. The mucoid isolate of I.
limosus grew in large quantities (≈105 CFU/mL) on B.
cepacia complex selective agar after 5 days of incubation.
In addition, ≈105 CFU/mL mucoid of P. aeruginosa, 103
CFU/mLof A. fumigatus and C. albicans were found in the
sputum sample. Colonies were oxidase- and catalase-posi-
tive and failed to grow on MacConkey agar. Api 20NE
showed  Sphingomonas paucimobilis with questionable
profile (Code 0424744), and identification was achieved
by 16S rDNA sequencing, as described above. The isolate
showed 99.3% sequence homology to the I. limosus type
strain (LMG 20952T). PFGE showed a different band pat-
tern, which suggests that this strain was different from
strain A and, thus, excluded cross-infection between both
patients (Figure).
The antimicrobial susceptibility of strain B was compa-
rable to that of strain A, apart from higher MIC values for
amikacin and gentamicin and lower values for ceftazidime
(Table). Like the first patient, this patient was also in good
health and active. At the time of sputum sampling, pul-
monary function and laboratory tests were not done, but a
pulmonary function test conducted 2 weeks before showed
a vital capacity of 2.96l (74% of predicted vital capacity)
and a forced expiratory volume 1 of 1.95l (77% of predict-
ed forced expiratory volume 1), leukocyte count and
erythrocyte sedimentation rate were normal, and C-reactive
protein was slightly elevated to 5.8 mg/L. During the fol-
lowing 2 months, 6 sputum samples were investigated, but
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Figure. Pulsed-field gel electrophoresis of Inquilinus limosus. M,
molecular weight marker 48.5 to 970 kbp (BioRad 170-3635); In,
Inquilinus limosus type strain LMG 20952; Ps, Pseudomonas
aeruginosa ATCC 27853.Inquilinus was not detected again, while P. aeruginosa was
still present in a concentration of 105 CFU/mL. The patient
moved to another CF clinic and was lost to follow-up. 
Conclusions
To our knowledge, isolation of I. limosus from clinical
samples has only been described in 1 study (8). The preva-
lence of this species in our CF clinic between May 2002
and September 2004 was 2.4%. The natural reservoir of I.
limosus has yet to be discovered, but its relatedness to
other nonfermentative rods suggests environmental
sources. Inquilinus might be overlooked in clinical sam-
ples because of its rather slow growth and failure to grow
on MacConkey agar. Recovery of Inquilinus can be
improved by using selective media containing polymyxin
B or colistin and ticarcillin, such as B. cepacia complex
selective agar, and prolonged incubation at 36°C. The nec-
essary duration of incubation has yet to be determined
since our isolates grew better at 36°C than at room temper-
ature. Identifying the species is difficult since it is not con-
tained in the databases of commercial identification kits
and its mucoid appearance may lead to confusion with
mucoid P. aeruginosa strains. This species’failure to grow
on MacConkey agar, positive oxidase reaction, and typical
antimicrobial susceptibility profile (see below) in respira-
tory samples of CF patients should arouse suspicion.
Identification of I. limosus can be confirmed by 16S rRNA
gene sequencing (8). I. limosus is able to persist in the res-
piratory tract of CF patients for several months. As with P.
aeruginosa, abundant amounts of mucus with I. limosus
infection may favor persistence and chronic infection.
However, the pathogenic role of I. limosus in the patients
described here is unclear. The stepwise deterioration of
pulmonary function seen in patient 1 may also be attrib-
uted to irregular intervals of inhalation and of elective
antimicrobial therapy. The patient had finished his educa-
tion and had started his first employment. 
I. limosus shows a distinct antimicrobial susceptibility
profile with high MICs for cotrimoxazole, most aminogly-
cosides, ampicillin, cefotaxime, and piperacillin/tazobac-
tam. Although ceftazidime and ciprofloxacin would be
interpreted as susceptible applying the NCCLS interpreta-
tion criteria for P. aeruginosa (12), strain Apersisted in the
respiratory tract of the patient for several months after
therapy with these substances. Inquilinus may be effective-
ly protected from the action of antimicrobial agents by
mucus production, and local host factors may also con-
tribute to colonization and persistency. Further studies are
necessary to evaluate the epidemiology and clinical impor-
tance of I. limosus as well as the therapeutic options in CF
patients and in other patient groups. For instance, screen-
ing large CF patient groups by selective culture methods or
molecular methods, like the use of specific fluorescence in
situ hybridization probes or polymerase chain reaction
assays, are desirable for assessing the epidemiology of the
species. Longitudinal studies of infected patients are valu-
able in evaluating the clinical relevance and the factors
influencing persistency of Inquilinus. 
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